Stock CMPX COMPASS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Compass Therapeutics, Inc.

Equities

CMPX

US20454B1044

Market Closed - Nasdaq
Other stock markets
 21:00:00 17/05/2024 BST 		5-day change 1st Jan Change
1.6 USD 0.00% Intraday chart for Compass Therapeutics, Inc. 0.00% +2.56%
05-13 Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
05-06 Top Premarket Gainers MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Top Premarket Gainers
Compass Therapeutics Gets FDA Fast-Track Designation for Biliary Tract Cancer Treatment
Compass Therapeutics, Inc. Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Compass Therapeutics, Inc. Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Compass Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Compass Therapeutics Reports Positive Result in Lung Cancer Treatment Trial -- Shares Rise
Compass Therapeutics, Inc. Announces Executive Changes, Effective January 9, 2024
Compass Therapeutics, Inc. Announces Chief Executive Officer Changes, Effective January 9, 2024
Compass Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Ankyra Therapeutics Names Robert V. Tighe as Chief Scientific Officer
Compass Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Compass Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Compass Therapeutics, Inc. Appoints Richard S. Lindahl as Class III Director, Member and Chairman of the Audit Committee
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
Compass Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022
Compass Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Compass Therapeutics, Inc. Announces Resignation of David Wurzer to Board of Directors and Committees
Compass Therapeutics, Inc. Appoints David Wurzer as Class III Director, Member and Chairman of the Audit Committee
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CMPX Stock
  4. News Compass Therapeutics, Inc.
  5. Other languages